2026-02-24
Alcohol, Aging, and Long-Term Health: What the Evidence Shows
Alcohol consumption interacts with aging biology in complex ways. This article covers the liver, brain, cardiovascular, and cancer evidence, plus what nutritional strategies can mitigate harm.
2026-02-20
Liver Enzyme Elevation Risk: Silymarin, NAC, and Berberine With Lifestyle First
Elevated liver enzymes improve most with weight, glucose, and alcohol correction. Silymarin, NAC, and berberine can be adjuncts in selected metabolic-risk contexts.
2026-02-18
CoQ10 and Mitochondrial Function: Age-Related Decline and Clinical Evidence
CoQ10 declines with age and statin exposure. Human evidence is strongest in heart failure and statin-associated muscle symptoms, while prevention use in healthy adults remains less certain.
2026-02-17
Caloric Restriction Mimetics in 2025: Multi-Pathway Geroprotectors Under Clinical Evaluation
A 2025 Biogerontology review maps geroprotective compounds targeting AMPK, mTOR, and autophagy pathways. Most remain at biomarker endpoints; hard longevity data in humans is largely absent.
2026-02-15
Silymarin (Milk Thistle): Liver Protection, MASLD Evidence, and Bioavailability Challenges
Silymarin (the active complex of milk thistle) has antioxidant and anti-inflammatory effects on hepatocytes. Evidence supports modest liver enzyme reduction in MASLD, though poor water solubility limits standard extract absorption. Phytosome forms show better bioavailability.